Cargando…

Sofosbuvir-based regimen is safe and effective for hepatitis C infected patients with stage 4–5 chronic kidney disease: a systematic review and meta-analysis

BACKGROUND: Whether sofosbuvir is suitable for hepatitis C virus (HCV) infected patients with severe renal impairment is inconclusive. This systematic review aims to evaluate the safety and effectiveness of SOF-based regimen in the setting of stage 4 and 5 chronic kidney disease (CKD). METHODS: We c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Mingshu, Chen, Jun, Fang, Zhixiong, Li, Yi, Lin, Qian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6419462/ https://www.ncbi.nlm.nih.gov/pubmed/30871566 http://dx.doi.org/10.1186/s12985-019-1140-x

Ejemplares similares

Incidence of Hepatocellular Carcinoma after Treatment with Sofosbuvir-Based or Sofosbuvir-Free Regimens in Patients with Chronic Hepatitis C
por: Ogawa, Eiichi, et al.
Publicado: (2020)

Sofosbuvir‐based regimens for the treatment of chronic hepatitis C in severe renal dysfunction
por: Cox‐North, Paula, et al.
Publicado: (2017)

Sofosbuvir and Velpatasvir Regimen Outcome for Chronic Hepatitis C Patients With End-Stage Renal Disease Undergoing Hemodialysis
por: Shahid, Salman, et al.
Publicado: (2023)

Treatment Outcomes for Patients Undergoing Hemodialysis with Chronic Hepatitis C on the Sofosbuvir and Daclatasvir Regimen
por: Butt, Nazish, et al.
Publicado: (2019)

Clinical and economic value of sofosbuvir-based regimens in the treatment of chronic hepatitis C in Spain
por: Esteban, Rafael, et al.
Publicado: (2022)

Efficacy and safety of sofosbuvir-containing regimens in patients with chronic hepatitis C virus infection after liver transplantation: a meta-analysis
por: Fu, Hua, et al.
Publicado: (2020)

Treatment of chronic hepatitis C in patients with chronic kidney disease with Sofosbuvir-basead regimes
por: Rossato, Giovana, et al.
Publicado: (2019)

Hemodialysis Patients Treated for Hepatitis C Using a Sofosbuvir-based Regimen
por: Agarwal, Sanjay Kumar, et al.
Publicado: (2017)

Changes in renal function indices in cirrhotic chronic hepatitis C patients treated with sofosbuvir-containing regimens
por: Chen, Jianhong, et al.
Publicado: (2017)

Sofosbuvir Based Regimens in the Treatment of Chronic Hepatitis C with Compensated Liver Cirrhosis in Community Care Setting
por: Gayam, Vijay, et al.
Publicado: (2018)

Efficacy and safety of Sofosbuvir-containing regimens in patients co-infected with chronic hepatitis C virus and human immunodeficiency virus: a meta-analysis
por: Li, Guotao, et al.
Publicado: (2018)

Sofosbuvir-based regimens in the treatment of patients with chronic hepatitis C virus infection: Real-world efficacy in Thailand
por: Sirinawasatien, Apichet, et al.
Publicado: (2020)

Sofosbuvir/velpatasvir regimen promises an effective pan-genotypic hepatitis C virus cure
por: Mir, Fazia, et al.
Publicado: (2017)

Efficacy and Safety of Sofosbuvir-based Regimens in Hepatitis C Patients With Decompensated Cirrhosis: A Systematic Review and Meta-analysis
por: Zhang, Wenyan, et al.
Publicado: (2023)

Real-World Single-Center Experience with Sofosbuvir-Based Regimens for the Treatment of Chronic Hepatitis C Genotype 1 Patients
por: Shin, Hyun Phil, et al.
Publicado: (2017)

Acute Kidney Injury in Patients Undergoing Chronic Hepatitis C Virus Treatment With Ledipasvir/Sofosbuvir
por: Brown, Patrick R., et al.
Publicado: (2018)

Sofosbuvir: a novel oral agent for chronic hepatitis C
por: Cholongitas, Evangelos, et al.
Publicado: (2014)

Safety and efficacy of sofosbuvir‐based medication regimens with and without ribavirin in hepatitis C patients: A systematic review and meta‐analysis
por: Elshafie, Shaimaa, et al.
Publicado: (2022)

An updated systematic review and meta-analysis on efficacy of Sofosbuvir in treating hepatitis C-infected patients with advanced chronic kidney disease
por: Majd Jabbari, Sara, et al.
Publicado: (2021)

Sofosbuvir/velpatasvir/voxilaprevir for hepatitis C
Publicado: (2019)

Efficacy and safety of sofosbuvir-based regimens for treatment in chronic hepatitis C genotype 1 patients with moderately impaired renal function
por: Shin, Hyun Phil, et al.
Publicado: (2017)

Cost-utility analysis of four WHO-recommended sofosbuvir-based regimens for the treatment of chronic hepatitis C in sub-Saharan Africa
por: Boyer, Sylvie, et al.
Publicado: (2022)

Cost-Effectiveness Analysis of Pan-Genotypic Sofosbuvir-Based Regimens for Treatment of Chronic Hepatitis C Genotype 1 Infection in China
por: Zhou, Hui Jun, et al.
Publicado: (2021)

Three regimens for re-treatment failure of Sofosbuvir-based therapy for chronic hepatitis-C genotype-4: a cohort study
por: Shousha, Hend Ibrahim, et al.
Publicado: (2022)

Outcomes after sofosbuvir-containing regimens for hepatitis C virus in patients with decompensated cirrhosis: a real-world study
por: Ji, Fanpu, et al.
Publicado: (2017)

Safe and effective sofosbuvir-based therapy in patients with mental health disease on hepatitis C virus treatment
por: Tang, Lydia Shuk Yee, et al.
Publicado: (2016)

Cost-effectiveness of sofosbuvir-based treatments for chronic hepatitis C in the US
por: Zhang, Sai, et al.
Publicado: (2015)

Sofosbuvir: A novel treatment option for chronic hepatitis C infection
por: Bhatia, Harmeet Kaur, et al.
Publicado: (2014)

Retinopathy and Uveitis Associated with Sofosbuvir Therapy for Chronic Hepatitis C Infection
por: Chin-Loy, Katrina, et al.
Publicado: (2016)

Assessment of auditory functions in chronic hepatitis C patients treated by sofosbuvir
por: Ismail, Elshahat Ibrahem, et al.
Publicado: (2018)

Real‐world treatment outcomes of sofosbuvir‐based regimens for treatment of chronic hepatitis C with and without human immunodeficiency virus co‐infection
por: Khemnark, Suparat, et al.
Publicado: (2023)

Use of sofosbuvir in chronic kidney disease: Is it necessary?
por: Lim, Tae Seop, et al.
Publicado: (2017)

Efficacy and safety of sofosbuvir and daclatasvir in treatment of kidney transplantation recipients with hepatitis C virus infection
por: Xue, Yan, et al.
Publicado: (2017)

Sofosbuvir-based Regimens with Task Shifting Is Cost-effective in Expanding Hepatitis C Treatment Access in the United States
por: Jayasekera, Channa R., et al.
Publicado: (2017)

Health utilities using SF-6D scores in Japanese patients with chronic hepatitis C treated with sofosbuvir-based regimens in clinical trials
por: Younossi, Zobair, et al.
Publicado: (2017)

Effectiveness of sofosbuvir based direct-acting antiviral regimens for chronic hepatitis C virus genotype 6 patients: Real-world experience in Vietnam
por: Nguyen, Dung Thanh, et al.
Publicado: (2020)

Subgroup Differences in Response to 8 Weeks of Ledipasvir/Sofosbuvir for Chronic Hepatitis C
por: O'Brien, Thomas R., et al.
Publicado: (2014)

Sofosbuvir for the treatment of chronic hepatitis C: between current evidence and future perspectives
por: Degasperi, Elisabetta, et al.
Publicado: (2014)

Correction: Retinopathy and Uveitis Associated with Sofosbuvir Therapy for Chronic Hepatitis C Infection
por: Chin Loy, Katrina, et al.
Publicado: (2016)

Decreasing racial disparity with the combination of ledipasvir–sofosbuvir for the treatment of chronic hepatitis C
por: Naylor, Paul H, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_72lqkevjuajvpbst2n2s1vp192